Statistik Asas
| CIK | 1581720 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Loxo Oncology, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| January 8, 2020 |
LOXO / Loxo Oncology, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 25, 2019 |
LOXO / Loxo Oncology, Inc. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact name of registrant as specified |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 S-8 POS 1 d663758ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 S-8 POS 1 d663758ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-197800 Registration No. 333-203081 Registration No. 333-210214 Registration No. 333-216503 Registration No. 333-223359 Registration No. 333-226734 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 |
|
| February 15, 2019 |
Amended and Restated Certificate of Incorporation of Loxo Oncology, Inc. EX-3.1 2 d664418dex31.htm EXHIBIT 3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LOXO ONCOLOGY, INC. 1. The name of the Corporation is: Loxo Oncology, Inc. 2. The address of the Corporation’s registered office in the State of Delaware is 160 Greentree Drive – Suite 101, in the city of Dover, County of Kent, State of Delaware, 19904. The name of its registered agent at such ad |
|
| February 15, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2019 LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 46-2996673 (Com |
|
| February 15, 2019 |
Amended and Restated Bylaws of Loxo Oncology, Inc. Exhibit 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LOXO ONCOLOGY, INC. (a Delaware corporation) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of Loxo Oncology, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, wit |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-218690 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-218690 UNDER THE SECURITIES ACT OF 1933 LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Cha |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on February 15, 2019 Registration No. 333-214392 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-214392 UNDER THE SECURITIES ACT OF 1933 LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Cha |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Loxo Oncology, Inc. (Name of Subject Company) Loxo Oncology, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 5488 |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 5 Activist Investment SC 13D/A 1 eh190023413da5-loxo.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| February 15, 2019 |
LOXO / Loxo Oncology, Inc. / LILLY ELI & CO - AMENDMENT NO. 3 TO SCHEDULE TO Amendment No. 3 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) LOXO ONCOLOGY, INC. (Name of Subject Company (Issuer)) BOWFIN ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Na |
|
| February 15, 2019 |
Lilly Completes Acquisition of Loxo Oncology Exhibit (a)(5)(C) Exhibit (a)(5)(C) February 15, 2019 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U. |
|
| February 13, 2019 |
LOXO / Loxo Oncology, Inc. / Adage Capital Partners GP LLC - LOXO ONCOLOGY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2019 |
LOXO / Loxo Oncology, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 11, 2019 |
LOXO / Loxo Oncology, Inc. / VANGUARD GROUP INC Passive Investment loxooncologyinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Loxo Oncology Inc Title of Class of Securities: Common Stock CUSIP Number: 548862101 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to |
|
| February 5, 2019 |
LLY / Eli Lilly & Co. AMENDMENT NO. 2 TO SCHEDULE TO Amendment No. 2 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) LOXO ONCOLOGY, INC. (Name of Subject Company (Issuer)) BOWFIN ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Na |
|
| February 5, 2019 |
LOXO / Loxo Oncology, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Loxo Oncology, Inc. (Name of Subject Company) Loxo Oncology, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| February 1, 2019 |
EX-(a)(5)(B) Exhibit (a)(5)(B) February 1, 2019 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U. |
|
| February 1, 2019 |
LOXO / Loxo Oncology, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Loxo Oncology, Inc. (Name of Subject Company) Loxo Oncology, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| February 1, 2019 |
LLY / Eli Lilly & Co. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) LOXO ONCOLOGY, INC. (Name of Subject Company (Issuer)) BOWFIN ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons |
|
| February 1, 2019 |
EX-(a)(5)(B) Exhibit (a)(5)(B) February 1, 2019 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U. |
|
| January 17, 2019 |
AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT EX-(e)(9) Exhibit (e) (9) AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between Jacob S. |
|
| January 17, 2019 |
AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT EX-(e)(10) Exhibit (e) (10) AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between Jennifer Burstein (the “Executive”) and Loxo Oncology, Inc. |
|
| January 17, 2019 |
AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT EX-(e)(11) Exhibit (e) (11) AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between Nisha Nanda (the “Executive”) and Loxo Oncology, Inc. |
|
| January 17, 2019 |
LOXO / Loxo Oncology, Inc. SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 17, 2019 |
EX-(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of LOXO ONCOLOGY, INC. |
|
| January 17, 2019 |
EX-(d)(3) Exhibit (d)(3) December 22, 2018 CONFIDENTIAL Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Ladies and Gentlemen: In connection with discussions between Eli Lilly and Company (“you”) and Loxo Oncology, Inc. |
|
| January 17, 2019 |
SC TO-T 1 d690054dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LOXO ONCOLOGY, INC. (Name of Subject Company (Issuer)) BOWFIN ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing |
|
| January 17, 2019 |
EX-(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of LOXO ONCOLOGY, INC. |
|
| January 17, 2019 |
EX-(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of LOXO ONCOLOGY, INC. |
|
| January 17, 2019 |
EX-(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of LOXO ONCOLOGY, INC. |
|
| January 17, 2019 |
EX-(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| January 15, 2019 |
LOXO / Loxo Oncology, Inc. / LILLY ELI & CO - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) Copies to: Michael J. Harrington General Counsel Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Tel: (317 |
|
| January 15, 2019 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Loxo Oncology, Inc., a Delaware corporation, and further agre |
|
| January 15, 2019 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 548862101 (CUSIP Number) Robert Wenzel Aisli |
|
| January 8, 2019 |
C O R P O R A T E P A R T I C I P A N T S EX-99.1 Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S Anne E. White Eli Lilly and Company - Senior VP & President of Lilly Oncology Daniel M. Skovronsky Eli Lilly and Company - Senior VP for Science & Technology & President of Lilly Research Labs David A. Ricks Eli Lilly and Company - Chairman, CEO & President Joshua L. Smiley Eli Lilly and Company - Senior VP & CFO Kevin Hern Levi Garraw |
|
| January 8, 2019 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Loxo Oncology, Inc. (Name of Subject Company (Issuer)) Bowfin Acquisition Corporation a wholly owned subsidiary of Eli Lilly and Company (Names of Filing Persons (Offerors)) Common Stock, $0.0001 par value per s |
|
| January 7, 2019 |
EX-99.4 Exhibit 99.4 Media Statement We are proud to be recognized for the innovative work we have done on behalf of cancer patients. We are excited by the prospect of our pipeline benefitting from the resources and global reach of the Lilly organization. Please direct questions about the specifics of the deal or integration plans to Lilly. Additional Information about the Acquisition and Where to |
|
| January 7, 2019 |
EX-99.3 Exhibit 99.3 Investor FAQ 1. When will more information about the transaction and negotiations be available? Lilly will initiate the tender offer process with a public filing of a tender offer document, and Loxo Oncology will make its own public filing at the same time. Please review these documents for additional background to the transaction. 2. Why sell now? Our Board has determined tha |
|
| January 7, 2019 |
EX-99.2 Exhibit 99.2 Employee FAQ 1. What was announced today? Eli Lilly and Loxo Oncology announced an agreement for the acquisition of Loxo Oncology for $235 per share, or approximately $8.0 billion. 2. Why does Lilly want to acquire Loxo Oncology? Lilly was looking for opportunities to expand the breadth of its precision medicine portfolio and recognized Loxo Oncology’s innovative approach and |
|
| January 7, 2019 |
EX-99.8 Exhibit 99.8 SAB E-mail Dear [NAME], Earlier today, it was announced that Loxo Oncology has agreed to be acquired by Eli Lilly. We are excited to see the medicines we are working on, in all stages of development, benefit from Lilly’s strong oncology presence, its rich history of innovation and its deep commitment to serving the needs of patients. As a key advisor to Loxo Oncology I wanted |
|
| January 7, 2019 |
EX-99.6 Exhibit 99.6 Supplier/Partner E-mail Dear [NAME], Earlier today, it was announced that Loxo Oncology has agreed to be acquired by Eli Lilly. The transaction is expected to close in the first quarter of 2019. We are excited to see our pipeline benefit from the resources, expertise and global reach of the Lilly organization. As a valued supplier / partner of Loxo Oncology, we wanted to reach |
|
| January 7, 2019 |
LOXO / Loxo Oncology, Inc. SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Loxo Oncology, Inc. (Name of Subject Company) Loxo Oncology, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUS |
|
| January 7, 2019 |
EX-99.5 Exhibit 99.5 E-mail Canceling JPM Meetings Dear XXX, Earlier today, it was announced today that Loxo Oncology has agreed to be acquired by Eli Lilly. Due to the announcement, Loxo Oncology management will not be in San Francisco for JPM and must cancel their meeting with you. For any questions on the proposed acquisition, please reference the press release and related SEC filings. Best, XX |
|
| January 7, 2019 |
EX-99.7 Exhibit 99.7 PIs/KOL E-mail Dear [NAME], Earlier today, it was announced that Loxo Oncology has agreed to be acquired by Eli Lilly. We are excited to see our pipeline benefit from the resources, expertise and global reach of the Lilly organization. As a key partner on our clinical trials we wanted to reach out and confirm that all of our ongoing studies will continue to run as usual. The t |
|
| January 7, 2019 |
EX-99.1 Exhibit 99.1 Internal E-mail Dear Team, A few moments ago, it was announced that Loxo Oncology has entered into a definitive agreement to be acquired by Eli Lilly. I imagine the news strikes you as both exciting and surprising at the same time. As the news sinks in, and the details are explained, I hope that you will come to feel humbled and grateful that five-and-a-half years of our hard |
|
| January 7, 2019 |
Joint Press Release issued by Eli Lilly and Company and Loxo Oncology, Inc., dated January 7, 2019. EX-99.1 Exhibit 99.1 January 7, 2019 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Lauren Cohen; [email protected]; (617) 678-2067 (Loxo Oncology) Peter Rahmer; pr |
|
| January 7, 2019 |
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2019 ELI LILLY AND COMPANY (Exact name of registrant as specified in its charter) Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| January 7, 2019 |
Investor Presentation of Eli Lilly and Company, dated January 2019. EX-99.2 Exhibit 99.2Exhibit 99.2 •• • • • • • • • • ••• • • • • • • • • • o o o o o o o o oo o o o o o o o o o o o o o oo o o o o o o o o o o o o oo o o o o o o o o o o oo o o o |
|
| January 7, 2019 |
Lilly Announces Agreement To Acquire Loxo Oncology EX-99.1 Exhibit 99.1 January 7, 2019 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media) Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors) Lauren Cohen; [email protected]; (617) 678-2067 (Loxo Oncology) Peter Rahmer; pr |
|
| January 7, 2019 |
EX-2.1 2 d674169dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 5, 2019, AMONG ELI LILLY AND COMPANY, BOWFIN ACQUISITION CORPORATION AND LOXO ONCOLOGY, INC. Table of Contents Page ARTICLE I THE OFFER 2 SECTION 1.01. The Offer 2 SECTION 1.02. Company Actions 4 ARTICLE II THE MERGER 5 SECTION 2.01. The Merger 5 SECTION 2.02. Merger Closing 5 SECTION 2. |
|
| January 7, 2019 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 5, 2019, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Bowfin Acquisition Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”), and each of the entities set forth on Schedu |
|
| January 7, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2019 LOXO ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36562 46-2996673 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 2, 2019 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| December 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 6, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 27, 2018 |
Exhibit 99.1 News Release FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion1,2 · First treatment with a tumor-agnostic indication at the time of initial FDA approval · 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in a |
|
| November 27, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 26, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 8, 2018 |
Exhibit 99.2 Corporate Presentation Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," |
|
| November 8, 2018 |
Exhibit 99.1 Loxo Oncology Reports Third Quarter 2018 Financial Results - Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 - - LOXO-292 Registrational Data Expected in 2019 - - LOXO-292 NDA Submission Expected in Late 2019 - - Enrollment of First Patient in LOXO-305 Phase 1/2 Study on Track for Fourth Quarter 2018 - STAMFORD, Conn., Nov. 08, 2018 — Loxo Oncology, Inc. (Nasd |
|
| November 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 8, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 8, 2018 |
LOXO / Loxo Oncology, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (E |
|
| September 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 15, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| September 6, 2018 |
LOXO / Loxo Oncology, Inc. CORRESP September 6, 2018 VIA EDGAR AND OVERNIGHT COURIER United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: James Rosenberg Christine Allen-Torney Lisa Vanjoske Re: Loxo Oncology, Inc. |
|
| August 9, 2018 |
LOXO / Loxo Oncology, Inc. S-8 S-8 1 a18-182491s8.htm S-8 As filed with the Securities and Exchange Commission on August 9, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2996673 (State or Other Jurisdiction of Incorporation or |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-1824928k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 9, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 46 |
|
| August 9, 2018 |
EX-99.1 2 a18-182492ex99d1.htm EX-99.1 Exhibit 99.1 Loxo Oncology Reports Second Quarter 2018 Financial Results - LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib Duration of Response Data to be Reported at ESMO - - Larotrectinib NDA PDUFA date is November 26, 2018 - STAMFORD, Conn., August 9, 2018 — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharm |
|
| August 9, 2018 |
LOXO / Loxo Oncology, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| August 9, 2018 |
Non-Plan Stock Option Agreement (Inducement Stock Option Award). Exhibit 10.2 LOXO ONCOLOGY NON-PLAN STOCK OPTION AGREEMENT (INDUCEMENT STOCK OPTION AWARD) This Stock Option Agreement (this “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Loxo Oncology, Inc., a Delaware corporation (the “Company”), and the optionee named below (“Optionee”). Capitalized terms not defined herein shall have the mean |
|
| August 9, 2018 |
2014 Equity Incentive Plan, as amended April 23, 2018 and forms of award agreements. Exhibit 10.1 LOXO ONCOLOGY, INC. |
|
| July 12, 2018 |
Amendment No. 3 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 548862101 (C |
|
| June 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 13, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 6, 2018 |
LOXO / Loxo Oncology, Inc. / ACCESS INDUSTRIES MANAGEMENT, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) Alejandro Moreno c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212) 247-6400 with |
|
| June 6, 2018 |
EX-99.1.1 2 d591520dex9911.htm EX-99.1.1 Exhibit 99.1.1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is |
|
| June 4, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 2, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 4, 2018 |
Exhibit 99.1 Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting — 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) — — Activity Observed Independent of RET Alteration, Tumor Type (Lung, Thyroi |
|
| June 4, 2018 |
2018 ASCO Conference June 2, 2018 Call 1 Exhibit 99.2 2018 ASCO Conference June 2, 2018 Call 1 Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "be |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-1305018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 8, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 46-29 |
|
| May 8, 2018 |
Exhibit 99.1 CONFIDENTIAL DRAFT - NOT FOR CIRCULATION Loxo Oncology Reports First Quarter 2018 Financial Results - LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting - - LOXO-292 Preclinical and Clinical Proof-of-Concept Data Published in Annals of Oncology - - Rolling Submission for Larotrectinib New Drug Application Completed - STAMFORD, Conn., May 8, 2018 — Loxo Oncology, I |
|
| May 8, 2018 |
Amended and Restated Employment Agreement Exhibit 10.2 May 8, 2018 Joshua H. Bilenker 281 Tresser Boulevard, 9th Floor Stamford, CT 06901 Re: Amended and Restated Offer of Employment by Loxo Oncology, Inc. Dear Josh: On behalf of Loxo Oncology, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) is very pleased to offer you this amended and restated employment agreement (the “Agreement”): 1. Position; Chief Executive |
|
| May 8, 2018 |
LOXO / Loxo Oncology, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| May 8, 2018 |
Form of Amended and Restated Change of Control and Severance Agreement EX-10.1 2 a18-86401ex10d1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between (the “Executive”) and Loxo Oncology, Inc., a Delaware corporation (the “Company”), on May , 2018 (the “Effective Date”). 1. Term of Agreement. Except to the extent rene |
|
| April 30, 2018 |
LOXO / Loxo Oncology, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2018 |
DEF 14A 1 a18-28321def14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for U |
|
| March 1, 2018 |
LOXO / Loxo Oncology, Inc. S-8 As filed with the Securities and Exchange Commission on March 1, 2018 Registration No. |
|
| March 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 1, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| March 1, 2018 |
Exhibit 99.1 Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results ? Larotrectinib Rolling NDA Submission on Track for Completion in March ? ? LOXO-292 Phase 1 Clinical Data Update Expected in First Half 2018 ? STAMFORD, Conn., March 1, 2018 ? Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with |
|
| March 1, 2018 |
Exhibit 10.20 AMENDMENT TO LEASE This AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of November 15, 2017 between ONE STAMFORD PLAZA OWNER LLC, a Delaware limited liability company (“Landlord”) and LOXO ONCOLOGY, INC., a Delaware corporation (“Tenant”). RECITALS: A. Landlord and Tenant are parties to that certain Office Lease Agreement dated as of October 6, 2015 (the “Lease”). |
|
| March 1, 2018 |
Exhibit 10.19 Execution Version LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BAYER CONSUMER CARE AG and LOXO ONCOLOGY, INC. November 14, 2017 [***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential trea |
|
| March 1, 2018 |
LOXO / Loxo Oncology, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-36562 LOXO ONCOLOGY, INC. |
|
| February 21, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: February 21, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| February 21, 2018 |
Exhibit 99.1 Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine ? Marked and Durable Responses Across TRK Fusion Cancers ? ? 75 Percent Overall Response Rate by Central Assessment; 80 Percent Overall Response Rate by Investigator Assessment ? ? 86 Percent of Responding Patients Remain on Larotrectinib or Underwent Surgery with Curative Intent |
|
| February 13, 2018 |
LOXO / Loxo Oncology, Inc. / Adage Capital Partners GP LLC - LOXO ONCOLOGY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2018 |
LOXO / Loxo Oncology, Inc. / VANGUARD GROUP INC Passive Investment SC 13G 1 loxooncologyinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Loxo Oncology Inc Title of Class of Securities: Common Stock CUSIP Number: 548862101 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designate the rule pursuant to whi |
|
| February 8, 2018 |
LOXO / Loxo Oncology, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 8, 2018 |
LOXO / Loxo Oncology, Inc. / VICTORY CAPITAL MANAGEMENT INC Passive Investment SC 13G/A 1 loxooncol13ga2123117.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 2 )* Loxo Oncology Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 24, 2018 |
EX-99.1.1 Exhibit 99.1.1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completenes |
|
| January 24, 2018 |
LOXO / Loxo Oncology, Inc. / ACCESS INDUSTRIES MANAGEMENT, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) Alejandro Moreno c/o Access Industries, Inc. 730 Fifth Avenue, 20th Floor New York, New York 10019 (212) 247-6400 with co |
|
| January 8, 2018 |
Exhibit 99.1 Corporate Presentation 1 Forward Looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project |
|
| January 8, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 8, 2018 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| December 27, 2017 |
LOXO / Loxo Oncology, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 22, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| December 4, 2017 |
Exhibit 99.1 Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers 94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent Larotrectinib Demonstrates Central Nervous System Activity with First-Ever TRK Fusion Glioblastoma Response with a TRK Inhibitor STA |
|
| December 4, 2017 |
LOXO / Loxo Oncology, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 4, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 28, 2017 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) Robert Wenzel Aisl |
|
| November 21, 2017 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 15, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 20, 2017 |
LOXO / Loxo Oncology, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment SC 13D/A 1 ss68415sc13da.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* LOXO ONCOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 548862101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York |
|
| November 20, 2017 |
EX-99.1 2 ss68415ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated November 20, 2017 (the “Schedule 13D”), with respect to the Common Stock, of Loxo Oncology, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) |
|
| November 14, 2017 |
Exhibit 99.1 Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195 ? Up to $1.55B in Upfront, Regulatory, and Commercial Milestones? ? Loxo Oncology and Bayer to Co-Promote in U.S. with a 50/50 Profit Share; Bayer to Commercialize ROW ? ? Loxo Oncology to Lead Global Development Activities ? ? Conference Call Today at 8:00 a.m. ET ? |
|
| November 14, 2017 |
LOXO / Loxo Oncology, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 14, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 2, 2017 |
Exhibit 99.01 Loxo Oncology Announces Third Quarter 2017 Financial Results ? Larotrectinib New Drug Application (NDA) Submission to U.S. FDA on Track for Year End 2017 / Early 2018 ? ? Clinical Proof-of-Concept Data Presented for LOXO-292 in RET Fusion Lung Cancer ? ? $405.3 million in Cash, Cash Equivalents, and Investments Provides Significant Runway ? STAMFORD, Conn., November 2, 2017 ? Loxo On |
|
| November 2, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 2, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (E |
|
| November 2, 2017 |
Exhibit 10.2 THIS ASSIGNMENT is made the 29 day of July 2017 (A) REDX PHARMA PLC and REDX ONCOLOGY LIMITED (both in administration) c/o FRP Advisory LLP, 110 Cannon Street, London, EC4N 6EU, UK (together the ?Assignor?); (B) LOXO ONCOLOGY, INC. a corporation whose offices are at 281 Tresser Boulevard, 9th Floor Stamford, CT 06901, USA (the ?Assignee?); and (C) JASON BAKER and MILES NEEDHAM both of |
|
| November 2, 2017 |
Exhibit 10.1 EXECUTION VERSION Date: 28 July 2017 REDX PHARMA PLC and REDX ONCOLOGY LIMITED (both in administration) c/o FRP Advisory LLP AND JASON BAKER and MILES NEEDHAM both of FRP Advisory LLP AND LOXO ONCOLOGY, INC. Agreement for the Assignment of Patents and other Rights and for the Novation of certain Agreements, including for Product Manufacturing Fieldfisher Riverbank House 2 Swan Lane Lo |
|
| October 18, 2017 |
Exhibit 99.1 Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset ? 75% Overall Response Rate by Independent Review; 80% Overall Response Rate by Investigator Assessment ? STAMFORD, Conn., October 18, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for |
|
| October 18, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 18, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| October 18, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 18, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| October 18, 2017 |
Exhibit 99.1 LOXO-292, a Potent, Highly Selective RET Inhibitor, in Multi-Kinase Inhibitor-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases Vamsidhar Velcheti1, Todd Bauer2, Vivek Subbiah3, Maria E. Cabanillas3, Nehal Lakhani4, Lori J. Wirth5, Geoffrey R. Oxnard6, Manisha H. Shah7, Eric J. Sherman8, Melissa Johnson2, Steven Smith9, Todd Eary9, Scott Cruickshank9 |
|
| September 28, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 27, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| September 28, 2017 |
LOXO-292, a potent, highly selective RET inhibitor, in MKI-resistant Exhibit 99.2 LOXO-292, a potent, highly selective RET inhibitor, in MKI-resistant RET fusion-positive lung cancer patients with and without brain metastases Authors: Vamisdhar Velcheti1, Todd Bauer2, Vivek Subbiah3, Maria E. Cabanillas3, Nehal Lakhani4, Lori J. Wirth5, Geoffrey R. Oxnard6, Manisha H. Shah7, Eric J. Sherman8, Steven Smith9, Todd Eary9, Scott Cruickshank9, Brian Tuch9, Kevin Ebata9, |
|
| September 28, 2017 |
Exhibit 99.1 Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer STAMFORD, Conn., Sept 27, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced details of the LOXO-292 abs |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a17-1895218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 8, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 46 |
|
| August 8, 2017 |
EX-99.01 2 a17-189521ex99d01.htm EX-99.01 Exhibit 99.01 Loxo Oncology Announces Second Quarter 2017 Financial Results — Larotrectinib NDA Submission on Track for Year End 2017 / Early 2018 — — Larotrectinib, LOXO-195, and LOXO-292 Clinical Trials Actively Enrolling — — $467.6 million in Cash, Cash Equivalents, and Investments Provides Significant Runway — STAMFORD, Conn., August 8, 2017 — Loxo Onc |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| July 31, 2017 |
Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program Exhibit 99.1 Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program STAMFORD, Conn., July 31, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has entered into a definitive agreement to purchase the Bruton? |
|
| July 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: July 28, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 23, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 a17-1569918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 22, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 46- |
|
| June 15, 2017 |
Loxo Oncology Prices Follow-On Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Loxo Oncology Prices Follow-On Offering of Common Stock STAMFORD, Conn., June 14, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 3,150,000 shares of common stock at a pub |
|
| June 15, 2017 |
Loxo Oncology, Inc. 3,150,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement Exhibit 1.1 Loxo Oncology, Inc. 3,150,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement New York, New York June 14, 2017 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Citigroup Glob |
|
| June 15, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 14, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 15, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS1 TABLE OF CONTENTS CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee(2) Common stock, $0. |
|
| June 13, 2017 |
SUBJECT TO COMPLETION, DATED JUNE 13, 2017 Use these links to rapidly review the document TABLE OF CONTENTS1 TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-218690 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 13, 2017 |
RATIO OF EARNINGS TO FIXED CHARGES Exhibit 12.1 RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth our dollar coverage deficiency. Any time we offer debt securities pursuant to this prospectus, we will provide an updated table setting forth our ratio of earnings to fixed charges on a historical basis in the applicable prospectus supplement, if required. Any time we offer shares of preferred stock pursuant to this pro |
|
| June 13, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on June 13, 2017 Registration No. |
|
| June 5, 2017 |
Exhibit 99.4 A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family Laetsch TW, 1 DuBois SG,2 Nagasubramanian R,3 Turpin B,4 Mascarenhas L,5 Federman N,6 Reynolds M,7 Smith S,7 Cruickshank S,7 Cox MC,7 Pappo AS,8 Hawkins DS9 1University of Texas Southwestern/Childrens Health, Dallas, TX; 2Dana-Farber/Boston Children's Cancer and Bl |
|
| June 5, 2017 |
2017 ASCO Conference Call June 4, 2017 1 Exhibit 99.5 2017 ASCO Conference Call June 4, 2017 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "be |
|
| June 5, 2017 |
Exhibit 99.3 The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers Hyman DM,1 Laetsch TW, 2 Kummar S,3 DuBois SG,4 Farago AF,5 Pappo AS,6 Demetri GD,7 El-Deiry WS,8 Lassen UN,9 Dowlati A,10 Brose MS,11 Boni V,12 Turpin B,13 Nagasubramanian R,14 Cruickshank S,15 Cox MC,15 Ku NC,15 Hawkins DS,16 Hong DS,17 Drilon |
|
| June 5, 2017 |
Exhibit 99.2 Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195 STAMFORD, Conn., June 3, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the online publication of a new research brief in Cancer Discovery |
|
| June 5, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 3, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 5, 2017 |
Exhibit 99.1 Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology Annual Meeting ? Responses to Selective TRK Inhibitor Observed Across Tumor Types Harboring TRK Fusions ? ? 93 Percent of All Responding Patients Remain on Larotrectinib or Receive |
|
| May 9, 2017 |
Loxo Oncology 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| May 9, 2017 |
Exhibit 99.01 Loxo Oncology Announces First Quarter 2017 Financial Results Larotrectinib Late-Breaking Oral Presentation at ASCO Annual Meeting on June 3, 2017 Company to Host ASCO Conference Call and Webcast on June 4, 2017 $244.3M in Cash, Cash Equivalents, and Investments Provide Runway to Mid-2019 STAMFORD, Conn., May 9, 2017 Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutica |
|
| May 9, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 9, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| May 1, 2017 |
*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 22, 2017. |
|
| May 1, 2017 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| March 21, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 15, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| March 21, 2017 |
Exhibit 16.1 March 21, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Loxo Oncology, Inc. in its Form 8-K dated March 21, 2017, which we understand will be filed with the Commission, pursuant to Item 4 of Form 8-K. We agree with the statements concerning our Firm in such Form 8-K. Very truly yours, /s/ CohnRez |
|
| March 7, 2017 |
As filed with the Securities and Exchange Commission on March 7, 2017 Registration No. |
|
| March 7, 2017 |
Loxo Oncology 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-36562 LOXO ONCOLOGY, INC. |
|
| March 7, 2017 |
Exhibit 10.5 March 6, 2017 Joshua H. Bilenker 78 Fieldstone Road Stamford, CT 06902-2577 Re: Amended and Restated Offer of Employment by Loxo Oncology, Inc. Dear Josh: On behalf of Loxo Oncology, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) is very pleased to offer you this amended and restated employment agreement (the “Agreement”): 1. Position; Chief Executive Office |
|
| March 7, 2017 |
Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results Exhibit 99.01 Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results STAMFORD, Conn., March 7, 2017 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported fourth quarter and year-end 2016 financial results. Loxo Oncology will not be conducting a confere |
|
| March 7, 2017 |
Form of Change in Control and Severance Agreement Exhibit 10.18 CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (this “Agreement”) is entered into by and between [·] (the “Executive”) and Loxo Oncology, Inc., a Delaware corporation (the “Company”), on March 6, 2017 (the “Effective Date”). 1. Term of Agreement. Except to the extent renewed as set forth in this Section 1, this Agreement shall terminate the e |
|
| March 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 7, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| February 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 1 )* Loxo Oncology Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 9, 2017 |
LOXO / Loxo Oncology, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 18, 2017 |
LOXO / Loxo Oncology, Inc. / ACCESS INDUSTRIES MANAGEMENT, LLC - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) Alejandro Moreno c/o Access Industries, Inc. 730 Fifth Avenue, 20th Floor New York, New York 10019 (212) 247-6400 with |
|
| January 18, 2017 |
EX-99.1 2 d243707dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is respons |
|
| January 12, 2017 |
EXHIBIT 6 LOXO ONCOLOGY, INC. January 3, 2017 Morgan Stanley & Co. LLC Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gen |
|
| January 12, 2017 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) Lloyd Appel Aislin |
|
| January 12, 2017 |
EXHIBIT 5 LOXO ONCOLOGY, INC. December 23, 2016 Morgan Stanley & Co. LLC Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and G |
|
| January 12, 2017 |
LOXO / Loxo Oncology, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* LOXO ONCOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 548862101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739‑6400 (Name, A |
|
| January 12, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated January 12, 2017 (the “Schedule 13D”), with respect to the Common Stock, of Loxo Oncology, Inc. |
|
| January 6, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 548862101 (CUSIP Number) December 28, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 5, 2017 |
3,870,000 Shares Loxo Oncology, Inc. Common Stock $31.00 per share Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-214392 PROSPECTUS SUPPLEMENT (To Prospectus dated November 2, 2016) 3,870,000 Shares Loxo Oncology, Inc. Common Stock $31.00 per share We are selling 3,870,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. We have granted the underwriters an option for a period of 30 days to |
|
| January 5, 2017 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 4, 2017 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| January 5, 2017 |
Loxo Oncology, Inc. 3,870,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement Exhibit 1.1 Loxo Oncology, Inc. 3,870,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement New York, New York January 4, 2017 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen |
|
| January 5, 2017 |
Loxo Oncology Prices Follow-On Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Loxo Oncology Prices Follow-On Offering of Common Stock STAMFORD, Conn., January 5, 2017 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 3,870,000 shares of common stock at a p |
|
| January 4, 2017 |
SUBJECT TO COMPLETION, DATED JANUARY 4, 2017 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-214392 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities, and we are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not perm |
|
| December 19, 2016 |
Exhibit 99.2 Clinical safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions David S. Hong1, Afshin Dowlati2, Howard A. Burris, III3, James J. Lee4, Marcia S. Brose5, Anna F. Farago6, Todd M. Bauer3, Matthew Taylor7, Alice T. Shaw6, Steve Smith8, Nisha Nanda8, Scott Cruickshank8, Michael C. Cox8, Robert C. Doebele9 1MD A |
|
| December 19, 2016 |
Exhibit 99.1 Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update ? Six of Seven TRK Fusion Patients Achieve Confirmed RECIST Partial Responses and All Remain in Response ? ? All TRK Fusion Patients Remain on Study With Median Follow-Up of 15 Cycles ? ? Company to Host Investor Conference Call and Webcast on Mo |
|
| December 19, 2016 |
Corporate Update December 19, 2016 1 Exhibit 99.4 Corporate Update December 19, 2016 1 Forward Looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believ |
|
| December 19, 2016 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 18, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| December 19, 2016 |
EX-99.3 4 a16-233511ex99d3.htm EX-99.3 Exhibit 99.3 Loxo Oncology Outlines Plans for Accelerated Path to U.S. FDA Approval for Larotrectinib (LOXO-101) and Provides Comprehensive Pipeline Update — Larotrectinib Approximately 85% Enrolled to Goal; Completion of Enrollment for Primary Efficacy Analysis Expected Early 2017 — — NDA Submission for Larotrectinib Expected Late 2017 or Early 2018 — — Comp |
|
| November 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Addres |
|
| November 14, 2016 |
LOXO ONCOLOGY, INC. 281 Tresser Boulevard 9th Floor Stamford, CT 06901 November 14, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dorrie Yale Erin Jaskot Re: Loxo Oncology, Inc. Registration Statement on Form S-3 Filed November 2, 2016 File No. 333-214392 Via EDGAR ? Acceleration Request Requested Date: Nove |
|
| November 9, 2016 |
Loxo Oncology Appoints Steve D. Harr, M.D., CFO of Juno Therapeutics, to Board of Directors Exhibit 99.1 Loxo Oncology Appoints Steve D. Harr, M.D., CFO of Juno Therapeutics, to Board of Directors STAMFORD, Conn., November 9, 2016 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the appointment of Steve D. Harr, M.D., to its board of directors. Dr. Harr |
|
| November 9, 2016 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 9, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 9, 2016 |
POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jennifer Burstein, Sara Slifka, Nanette Agustines and Winston Macaraeg and each of them, as his true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of Loxo Oncology, Inc. |
|
| November 2, 2016 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] LOXO ONCOLOGY, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURIT |
|
| November 2, 2016 |
Table of Contents As filed with the Securities and Exchange Commission on November 2, 2016 Registration No. |
|
| November 2, 2016 |
LOXO ONCOLOGY, INC. Ratio of Earnings to Fixed Charges Exhibit 12.1 LOXO ONCOLOGY, INC. Ratio of Earnings to Fixed Charges The following table sets forth our dollar coverage deficiency. The ratio of earnings to fixed charges is not disclosed since it is a negative number in each year and period shown below. Any time we offer debt securities pursuant to this prospectus, we will provide an updated table setting forth our ratio of earnings to fixed charg |
|
| November 2, 2016 |
LOXO ONCOLOGY, INC. , as Trustee Dated as of , Exhibit 4.4 LOXO ONCOLOGY, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION |
|
| November 2, 2016 |
Loxo Oncology 10-Q (Quarterly Report) 10-Q 1 a16-17171110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 00 |
|
| November 2, 2016 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 2, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 2, 2016 |
Exhibit 99.01 Loxo Oncology Announces Third Quarter 2016 Financial Results ? Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Presentation at ESMO Asia on December 18, 2016 ? ? Company to Provide LOXO-101 Program and Pipeline Update During Conference Call and Webcast on Monday, December 19, 2016 at 8:00AM ET ? STAMFORD, Conn., November 2, 2016 ? Loxo Oncology, Inc. (Nasdaq:LOXO), a biophar |
|
| September 23, 2016 |
LOXO / Loxo Oncology, Inc. / RS INVESTMENT MANAGEMENT CO LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) July 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| September 23, 2016 |
Loxo Oncology LOXO ONCOLOGY 13G 073116 (Passive Acquisition of More Than 5% of Shares) SC 13G 1 loxooncology13g073116.htm LOXO ONCOLOGY 13G 073116 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Loxo Oncology Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) Victory Capital Management Inc., 4900 Tiedeman Rd, 4th Floor, Brooklyn, OH 44144 (216) 89 |
|
| September 13, 2016 |
SC 13D/A 1 loxo13da117989.htm SCHEDULE 13DA (AMEND. #1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Su |
|
| August 12, 2016 |
Loxo Oncology AMENDMENT NO. 3 (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LOXO ONCOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 548862101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, A |
|
| August 12, 2016 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 12, 2016 (the ?Schedule 13D?), with respect to the Common Stock of Loxo Oncology, Inc. |
|
| August 12, 2016 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 12, 2016 (the ?Schedule 13D?), with respect to the Common Stock of Loxo Oncology, Inc. |
|
| August 5, 2016 |
Loxo Oncology AMENDMENT NO. 2 (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LOXO ONCOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 548862101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, A |
|
| August 5, 2016 |
EX-99.1 2 ss5702ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 5, 2016 (the “Schedule 13D”), with respect to the Common Stock, of Loxo Oncology, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) unde |
|
| August 3, 2016 |
Loxo Oncology 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| August 3, 2016 |
Loxo Oncology Announces Second Quarter 2016 Financial Results Exhibit 99.01 Loxo Oncology Announces Second Quarter 2016 Financial Results STAMFORD, Conn., August 3, 2016 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the second quarter ended June 30, 2016. Loxo Oncology will not be conducting a confere |
|
| August 3, 2016 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: August 3, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| June 13, 2016 |
Loxo Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: June 10, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| May 27, 2016 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - SCHEDULE 13D Activist Investment SC 13D 1 eh1600646sc13d-loxo.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities |
|
| May 27, 2016 |
EXHIBIT 4 JOINT FILING AGREEMENT Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit (the “Schedule 13D”), and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. |
|
| May 27, 2016 |
EXHIBIT 1 LOXO ONCOLOGY, INC. May 11, 2016 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: This letter is being delivered to you in connection with the proposed Underwriting |
|
| May 27, 2016 |
EXHIBIT 2 LOXO ONCOLOGY, INC. May 11, 2016 Citigroup Global Markets Inc. Cowen and Company, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: This letter is being delivered to you in connection with the proposed Underwriting |
|
| May 12, 2016 |
Loxo Oncology, Inc. 1,675,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement Exhibit 1.1 Loxo Oncology, Inc. 1,675,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement New York, New York May 11, 2016 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 L |
|
| May 12, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 11, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| May 12, 2016 |
Loxo Oncology Prices Follow-On Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Loxo Oncology Prices Follow-On Offering of Common Stock STAMFORD, Conn., May 11, 2016 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 1,675,000 shares of common stock at a publ |
|
| May 12, 2016 |
1,675,000 Shares Loxo Oncology, Inc. Common Stock $21.50 per share 424B5 1 a2228613z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206052 PROSPECTUS SUPPLEMENT (To Prospectus dated August 3, 2015) 1,675,000 Shares Loxo Oncology, Inc. Common Stock $21.50 per share We are selling 1,675,000 shares of our common stock pursuant to this prospectus |
|
| May 11, 2016 |
SUBJECT TO COMPLETION, DATED May 11, 2016 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 4, 2016 |
Loxo Oncology 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (Exact |
|
| May 4, 2016 |
Loxo Oncology Announces First Quarter 2016 Financial Results Exhibit 99.1 Loxo Oncology Announces First Quarter 2016 Financial Results STAMFORD, Conn., May 4, 2016 ? Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2016. Loxo Oncology will not be conducting a conference c |
|
| May 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: May 4, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| April 18, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| April 18, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| April 18, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 17, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| April 18, 2016 |
Exhibit 99.1 Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update ? Five of Six Evaluable Patients with TRK Fusion Cancers Achieve Confirmed RECIST Partial Responses; All Six Demonstrate Significant Tumor Regressions ? ? All TRK Fusion Patients Remain on Study, With Longest Follow-up Beyond One Year ? ? Company to Host Investor Con |
|
| April 18, 2016 |
Exhibit 99.2 Clinical safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions David S. Hong1, Anna F. Farago2, Marcia S. Brose3, Howard A. Burris, III4, Afshin Dowlati5, Todd M. Bauer4, Matthew Taylor6, Alice T. Shaw2, Adriana Estrada-Bernal7, Anh T. Le7, Nisha Nanda8, Michael C. Cox8, Robert C. Doebele7 April 17, 2016 1 |
|
| March 15, 2016 |
As filed with the Securities and Exchange Commission on March 15, 2016 Registration No. |
|
| March 15, 2016 |
Loxo Oncology 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-36562 LOXO ONCOLOGY, INC. |
|
| March 15, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: March 15, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| March 15, 2016 |
Exhibit 99.01 Loxo Oncology Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Program Updates ? Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Plenary Session Presentation at 2016 AACR Annual Meeting ? ? LOXO-195, Next-Generation Selective TRK Inhibitor Addressing Potential Acquired Resistance, to Enter the Clinic in 2017 ? ? Cash Position Funds Operations Well Into |
|
| March 15, 2016 |
Separation and Consulting Agreements by and between Dr. Jennifer Low and the Registrant Exhibit 10.17 CONFIDENTIAL TREATMENT REQUESTED November 30, 2015 Via Email Jennifer Low, M.D., Ph.D., M.H.Sc. Re: Terms of Transition and Separation Dear Dr. Low: This letter confirms the agreement (“Agreement”) between you and Loxo Oncology, Inc. (the “Company”) concerning the terms of your transition and separation from employment and offers you certain benefits to which you would not otherwise |
|
| March 15, 2016 |
Amendment No. 5 to Drug Discovery and Collaboration Agreement, dated February 18, 2016 EXHIBIT 10.16 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 5 TO DRUG DISCOVERY COLLABORATION AGREEMENT THIS AMENDMENT NO.5 TO DRUG DISCOVERY COLLABORATION AGREEMENT (“Amendment”), effective February 18, 2016 (the “Amendment Date”), is by and between Array BioPharma Inc., a Delaware corporation (“Array”), and Loxo Oncology, Inc., a Delaware corporation (“Loxo”). WHEREAS, the parties previously en |
|
| March 8, 2016 |
Unassociated Document POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jennifer Burstein, Sara Slifka, Julia Forbess, Nanette A. |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Loxo Oncology, Inc (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862 10 1 (CUSIP Number) De |
|
| February 16, 2016 |
LOXO / Loxo Oncology, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 16, 2016 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 16, 2016 with respect to the shares of Common Stock of Loxo Oncology, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under th |
|
| February 12, 2016 |
Loxo Oncology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Loxo Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 11, 2016 |
Amendment No. 1 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 11, 2016 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated February 10, 2016 relating to the Common Stock, par value $0.0001 of Loxo Oncology, Inc. shall be filed on behalf of the undersigned. AI LOXO HOLDINGS LLC By: Access Industries Management, LLC, its Manager /s/ Alejandro Moreno Signature Alejandro Moreno / Executive Vice President Name/Title AI LOXO HOLDI |
|
| February 5, 2016 |
LOXO / Loxo Oncology, Inc. / AISLING CAPITAL III LP - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Loxo Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 548862101 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 7, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: January 5, 2016 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 19, 2015 |
LOXO / Loxo Oncology, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LOXO ONCOLOGY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 548862101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, A |
|
| November 19, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated November 19, 2015 (the “Schedule 13D”), with respect to the Common Stock, of Loxo Oncology, Inc. |
|
| November 12, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a15-2262648k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 11, 2015 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 |
|
| November 12, 2015 |
2,500,000 Shares Loxo Oncology, Inc. Common Stock $26.50 per share Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 12, 2015 |
Loxo Oncology, Inc. 2,500,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement EX-1.1 2 a15-226264ex1d1.htm EX-1.1 Exhibit 1.1 Loxo Oncology, Inc. 2,500,000 Shares(1) Common Stock ($0.0001 par value) Underwriting Agreement New York, New York November 11, 2015 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Le |
|
| November 12, 2015 |
Loxo Oncology Prices Follow-On Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Loxo Oncology Prices Follow-On Offering of Common Stock STAMFORD, Conn., November 11, 2015 ? Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a |
|
| November 12, 2015 |
SUBJECT TO COMPLETION, DATED NOVEMBER 10, 2015 424B5 1 a2226516z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206052 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities, |
|
| November 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 10, 2015 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
|
| November 10, 2015 |
Loxo Oncology Announces Third Quarter 2015 Financial Results and Provides Program Updates Exhibit 99.1 Loxo Oncology Announces Third Quarter 2015 Financial Results and Provides Program Updates STAMFORD, Conn., November 10, 2015 (GLOBE NEWSWIRE) Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2 |
|
| November 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36562 LOXO ONCOLOGY, INC. (E |
|
| November 10, 2015 |
Exhibit 10.1 TWO STAMFORD PLAZA STAMFORD, CONNECTICUT OFFICE LEASE AGREEMENT BETWEEN ONE STAMFORD PLAZA OWNER LLC (?LANDLORD?) AND LOXO ONCOLOGY, INC. (?TENANT?) TABLE OF CONTENTS Page TABLE OF CONTENTS 1. Basic Lease Information 1 2. Lease Grant 3 3. Adjustment of Commencement Date; Possession 3 4. Rent 4 5. Compliance with Laws; Use; Hazardous Materials 4 6. Security Deposit 6 7. Building Servic |
|
| November 9, 2015 |
Exhibit 99.1 Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial Six Patients with TRK Fusion Cancers Enrolled; All Remain on Study Three Patients with TRK Fusion Cancers Evaluable for Efficacy and All Show Objective Responses Company to Host Investor Conference Call and Webcast to Review the Data on Monday, November 9, 2015 at 8:00 a |
|
| November 9, 2015 |
Exhibit 99.2 Clinical safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions David S. Hong1, Marcia S. Brose2, Robert C. Doebele3, Alice T. Shaw4, Afshin Dowlati5, Todd M. Bauer6, Anna F. Farago4, Adriana Estrada-Bernal3, Anh T. Le3, Michael C. Cox7, Nisha Nanda7, Jennifer A. Low7, Howard A. Burris, III6 November 8, 2015 |
|
| November 9, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a15-2242528k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 8, 2015 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 |
|
| November 5, 2015 |
8-K 1 a15-2242518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 5, 2015 (Date of earliest event reported) LOXO ONCOLOGY, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36562 |
|
| November 5, 2015 |
Loxo Oncology Announces Transition of Chief Medical Officer Exhibit 99.1 Loxo Oncology Announces Transition of Chief Medical Officer STAMFORD, Conn., November 5, 2015 ? Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Jennifer Low, M.D., Ph.D., chief medical officer and executive vice president, R&D, has decided to tran |
|
| October 13, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: October 6, 2015 (Date of earliest event reported) LOXO ONCOLOGY, INC. |
